Sunday, February 28, 2021
Home Industries Pharma FDC launches two favipiravir variants for COVID-19 treatment

FDC launches two favipiravir variants for COVID-19 treatment

National, August 26, 2020: FDC announced the launch of two variants of favipiravir – PiFLU and Favenza – which will be used to treat mild to moderate cases of COVID-19 in India.

Earlier this year, the Drug Controller General of India (DCGI) approved the use of favipiravir, an off-patent, oral anti-viral drug that has been shown to quicken clinical recovery in COVID-19 patients with mild to moderate symptoms. It is a broad-spectrum antiviral agent, and selectively inhibits RNA polymerase of influenza and SARCOV-2 virus and prevents viral replication according to the reports published in

Commenting on the development, spokesperson of FDC, Mayank Tikkha, said, “We will be working with the government and healthcare fraternity to make Favenza and Piflu available across the country”.

FDC’s PiFLU and Favenza is currently available across the country.


Please enter your comment!
Please enter your name here

- Advertisment -

Most Popular

VitrA’s Plural: An Aura of Luxury

National, February 26, 2021: VitrA, the leading bathroom solutions brand of Eczacıbaşı Building Products Division introduces its Plural Series. Designed by award-winning designer Terri Pecora in...

FOLD 80 EF Sliding Solutions by Häfele

National, February 23, 2021: Sliding doors have always been the gateway into any place but in recent times they have surpassed that functionality to...

Sharp Spike in Cases of Mature Cataract and Dry Eyes during Pandemic

Bengaluru, February 23, 2021: The ongoing pandemic has led to increased severity and morbidity in eye conditions of people in Bengaluru because of delayed treatment...

Sri Lanka Fast Bowler Lahiru Kumara Tests Positive For Coronavirus

New Delhi, February 23, 2021: Sri Lanka bowler Lahiru Kumara, picked up for the white ball squad, has tested positive for coronavirus ahead of...

Recent Comments